David Rosenbaum Biography and Net Worth

Insider of Ardelyx


Dr. David P. Rosenbaum, Ph.D. is Chief Development Officer of the Company. From 2003 to 2008, he was Vice President of Drug Development for Trine Pharmaceuticals, Inc., a biopharmaceutical company, where he was developing a novel non-systemic therapeutic for the treatment of IBS. In addition, Dr. Rosenbaum previously served as Vice President of Preclinical Research and Development at GelTex Pharmaceuticals, a biopharmaceutical company, where he was responsible for the preclinical development of Renagel and Welchol. He received a B.A. in Biology from the University of Pennsylvania, a M.S. in Toxicology from Albany Medical College and a Ph.D. in Pharmacology from Boston University School of Medicine.

What is David P. Rosenbaum's net worth?

The estimated net worth of David P. Rosenbaum is at least $754,254.56 as of November 6th, 2024. Dr. Rosenbaum owns 153,616 shares of Ardelyx stock worth more than $754,255 as of January 21st. This net worth estimate does not reflect any other assets that Dr. Rosenbaum may own. Additionally, Dr. Rosenbaum receives an annual salary of $645,400.00 as Insider at Ardelyx. Learn More about David P. Rosenbaum's net worth.

How old is David P. Rosenbaum?

Dr. Rosenbaum is currently 63 years old. There are 6 older executives and no younger executives at Ardelyx. The oldest executive at Ardelyx is Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer, who is 64 years old. Learn More on David P. Rosenbaum's age.

What is David P. Rosenbaum's salary?

As the Insider of Ardelyx, Inc., Dr. Rosenbaum earns $645,400.00 per year. There are 3 executives that earn more than Dr. Rosenbaum. The highest earning executive at Ardelyx is Mr. Michael G. Raab, President, CEO & Director, who commands a salary of $1,030,000.00 per year. Learn More on David P. Rosenbaum's salary.

How do I contact David P. Rosenbaum?

The corporate mailing address for Dr. Rosenbaum and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at investor@ardelyx.com. Learn More on David P. Rosenbaum's contact information.

Has David P. Rosenbaum been buying or selling shares of Ardelyx?

David P. Rosenbaum has not been actively trading shares of Ardelyx during the last ninety days. Most recently, David P. Rosenbaum sold 27,171 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $6.10, for a transaction totalling $165,743.10. Following the completion of the sale, the insider now directly owns 153,616 shares of the company's stock, valued at $937,057.60. Learn More on David P. Rosenbaum's trading history.

Who are Ardelyx's active insiders?

Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.

Are insiders buying or selling shares of Ardelyx?

In the last year, Ardelyx insiders bought shares 1 times. They purchased a total of 213,300 shares worth more than $996,111.00. In the last year, insiders at the biopharmaceutical company sold shares 41 times. They sold a total of 1,118,423 shares worth more than $7,827,503.71. The most recent insider tranaction occured on January, 7th when CEO Michael Raab sold 41,666 shares worth more than $221,246.46. Insiders at Ardelyx own 5.9% of the company. Learn More about insider trades at Ardelyx.

Information on this page was last updated on 1/7/2025.

David P. Rosenbaum Insider Trading History at Ardelyx

David P. Rosenbaum Buying and Selling Activity at Ardelyx

This chart shows David P Rosenbaum's buying and selling at Ardelyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$600k-$400k-$200k$0$200k$400k$600kTotal Insider BuyingTotal Insider Selling

Ardelyx Company Overview

Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $4.91
Low: $4.85
High: $5.14

50 Day Range

MA: $5.15
Low: $4.50
High: $5.88

2 Week Range

Now: $4.91
Low: $4.32
High: $10.13

Volume

5,343,396 shs

Average Volume

5,430,712 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85